Thursday, 2 May, 2024
HomeWeekly RoundupNew EU task force to explore using big data to improve health

New EU task force to explore using big data to improve health

A new task force has been set up to explore how medicines regulators in the EU can use big data to improve human and animal health.

The task force has been established by the European Medicines Agency (EMA), in conjunction with the EEA Heads of Medicines Agencies (HMA), and was announced 23 March 2017.

The announcement follows a workshop held by EMA in mid-November 2016, where organisations including IBM Watson Health, Google Cloud Platform, UK Biobank, the European Federation of Pharmaceutical Industries and Associations and several academic institutions spoke about how to identify opportunities for big data in medicines development and regulatory science.

This new task force aims to leverage big data for health improvements through supporting research, innovation and robust medicines development.

Big data can be used for large-scale information processing which enables the development of more useful information and insights about customers and users, and may be used in, for example, process automation or improved decision making. It will usually require specialised computational tools to enable its analysis and exploitation.

Big data that may be useful to improving health includes electronic patient records, genomics, social media content, clinical trials, and spontaneous adverse reaction reports. Further innovations in healthcare, such as the use of apps to monitor glucose levels or review blood test results for signs of acute kidney issues, will only increase the amount of big data which could be used to improve health.

The task force is chaired jointly by the EMA and Danish Medicines agencies, and staffed with members from EEA medicines regulatory agencies. The task force includes representatives from Germany, Denmark, Spain, Finland, Hungary, Ireland, Netherlands, Norway, Romania, and the UK. Their work may be supported as needed by experts in big data analysis.

The EMA said that the vast volume of data has the potential to contribute significantly to the way the benefits and risks of medicines are assessed over their entire lifecycle.

[link url="http://www.cms-lawnow.com/ealerts/2017/04/ema–hma-establish-task-force-to-explore-big-datas-potential-for-human-health?cc_lang=en&ec_as=CCCB315DBD744EC8A600ED1EF2EB7C38"]CMS-Law material[/link]

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.